Development and immunogenicity of recombinant GapA Mycoplasma gallisepticum vaccine strain ts-11 expressing infectious bronchitis virus-S1 glycoprotein and chicken interleukin-6

PK Shil; A Kanci; GF Browning; PF Markham

Journal article

Development and immunogenicity of recombinant GapA Mycoplasma gallisepticum vaccine strain ts-11 expressing infectious bronchitis virus-S1 glycoprotein and chicken interleukin-6

PK Shil, A Kanci, GF Browning, PF Markham

Vaccine | ELSEVIER SCI LTD | Published : 2011

DOI: 10.1016/j.vaccine.2011.02.035

Abstract

Mycoplasma gallisepticum (MG) is a major pathogen of poultry that causes chronic respiratory disease in chickens and infectious sinusitis in turkeys. A live attenuated vaccine, ts-11, has been used for the control of MG in several countries. The efficacy of this vaccine is highly dose dependent and the flock antibody response is weak. To improve the functionality of the vaccine and investigate its potential as a delivery vector for foreign antigens and immunomodulatory proteins, we developed a derivative of ts-11 expressing infectious bronchitis virus-S1 glycoprotein (IBV-S1) and releasing chicken interleukin-6 into the extracellular milieu (MG ts-11 C3 (+CS)) using a transposon-based delive..

View full abstract

University of Melbourne Researchers

Anna Kanci Condello Author

Glenn Browning Author

Pollob Shil Author

Grants

Funding Acknowledgements

The authors gratefully acknowledge the assistance of Associate Professor Amir H. Noormohammadi, Dr. Marc Marenda, Cheryl Colson, June Daly, Josie Wilson, Rebecca Agnew, Faye Docherty, Shukriti Sharma and Shaiful Islam. This work was supported by an International Postgraduate Research Scholarship (IPRS) from the Australian Government and a Melbourne International Research Scholarship (MIRS) from The University of Melbourne.